T2 Biosystems Inc

Gold Sponsor

At T2 Biosystems, our mission is to improve sepsis management by empowering clinicians to appropriately treat patients suspected of bloodstream infections faster than ever before. T2 Biosystems accurately identifies pathogenic organisms associated with sepsis in 3 to 5 hours without the wait of blood culture, which can take 1 to 5 or more days. The T2Direct Diagnostics™ suite of products are the first and only FDA-cleared tests that identify sepsis causing pathogens directly from whole blood. Both the T2Bacteria® and T2Candida® Panels are run on the T2Dx® Instrument, and provide meaningful results that may enable changes in clinical outcomes. Assay results provide data to clinicians helping to identify appropriate therapy faster, improve patient outcomes, advance stewardship, and reduce the cost of patient management. T2Biosystems has a strong pipeline of products in development, including the T2ResistanceTM Panel which received “Breakthrough Device” designation from the FDA earlier this year, the T2Lyme® Panel, as well as the T2Candida aurisTM Panel RUO for the direct-from-blood or environmental detection of the deadly superbug, Candida auris.
 



website


GET INVOLVED AT

WORLD ANTI-MICROBIAL RESISTANCE CONGRESS

 

To Sponsor Or Exhibit

 


André Singer
andre.singer@terrapinn.com
+1 646.619.1797

 

 

Press & Media Partnerships

 


Shannon McGorry
shannon.mcgorry@terrapinn.com
+1 646.619.1840

 

 

To Speak

 


Claire Murphy
claire.murphy@terrapinn.com
+1 646.619.1784

 

Sign Up for Event Updates